Envestnet Asset Management Inc. Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Envestnet Asset Management Inc. increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 5.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 60,880 shares of the biotechnology company’s stock after acquiring an additional 2,889 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.14% of United Therapeutics worth $21,481,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in UTHR. Grantham Mayo Van Otterloo & Co. LLC lifted its stake in United Therapeutics by 101.2% in the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 8,227 shares of the biotechnology company’s stock valued at $2,903,000 after buying an additional 4,139 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new position in shares of United Therapeutics during the fourth quarter valued at approximately $6,902,000. Integrated Quantitative Investments LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $392,000. ExodusPoint Capital Management LP acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $1,899,000. Finally, World Investment Advisors increased its position in shares of United Therapeutics by 18.4% during the fourth quarter. World Investment Advisors now owns 1,299 shares of the biotechnology company’s stock worth $458,000 after purchasing an additional 202 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $284.31 on Tuesday. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The firm has a market capitalization of $12.77 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 0.97 and a beta of 0.63. The stock has a 50 day moving average of $321.83 and a 200 day moving average of $350.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same period last year, the company earned $4.36 EPS. Analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $955,319.67. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 77,500 shares of company stock worth $26,994,480. 11.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on UTHR shares. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.